{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-061980","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.266670+00:00","generated_at":"2026-05-18T23:09:31.021868+00:00","sec_items":["1.01","2.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Acura gets $200k more loans from AD Pharma; warns cash may run out by mid-July 2025","bullets":["Principal balance on AD Pharma secured note now $8,194,279; accrued interest ~$721k.","Two new $100k loans received June 3 and June 20, 2025; interest at 5.25% (7.5% default).","AD Pharma, which owns 65% of Acura's common stock, is the lender; controlled by Mr. Schutte.","Without additional financing by mid-July 2025, Acura may furlough/lay off employees or seek bankruptcy protection.","Company states no assurance additional financing will be obtained; proceeds used for day-to-day operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-061980","json":"https://secwatch.observer/filing/0001104659-25-061980.json","markdown":"https://secwatch.observer/filing/0001104659-25-061980.md","text":"https://secwatch.observer/filing/0001104659-25-061980.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465925061980/0001104659-25-061980-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465925061980/tm2518762d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:09:31.021868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14e1d33782b14be3e4b9505e3eab98173490c458","claim":"ACURA PHARMACEUTICALS, INC incurred loan of loans of $100,000 with Abuse Deterrent Pharma, LLC at 5.25%.","evidence_excerpt":"On each of June 3, 2025 and June 20, 2025, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (\"AD Pharma\"). These loans combined with previous loans made to the Company and combined with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now has a principal balance of $8,194,279 with accrued interest of approximately $721,000 as of June 20 2025, and bears interest at 5.25% (\"Note\").","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465925061980/0001104659-25-061980-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"loans of $100,000"},{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC"},{"label":"Rate","value":"5.25%"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}